Updated House User Fee Draft Highlights Lack of Consensus on Track-and-Trace System

The House has updated its draft of omnibus FDA user fee legislation with much-anticipated language on supply chain safety. But like the Senate bill, it lacks provisions to authorize a U.S. track-and-trace system, leaving the agency priority in doubt. The latest version of the lower chamber’s user fee draft includes supply chain provisions that would increase criminal penalties for counterfeiters, ease sharing of trade secret information between the FDA and foreign governments and generally boost oversight on imported products.
Drug Industry Daily